VBTC
Asset Logo

VanEck Bitcoin ETF

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ“™ Holdings

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 13.74%
Growth

5 months growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

80
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

VBTC.AX was created on 2024-06-18 by VanEck. The fund's investment portfolio concentrates primarily on long btc, short usd currency. The fund aims to provide a return that tracks the performance of the price of Bitcoin, before fees and other costs.

🌐 Website

πŸ“ˆ Performance

Price History

+5.18%

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ“™ Top Holdings

Show more

Top holdings information is not yet available for this fund. For more information please visit the fund manager's website.

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

0.59%
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$21.10

πŸ’° Price To Earnings Ratio

0.00

πŸ’° Price To Book Ratio

0.00

πŸ’° Leveraged

No

πŸ’° Inverse

No

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in VBTC

81

πŸ“Š Total Capital Earnings

$106K

πŸ”ƒ Average investment frequency

26 weeks

πŸ’΅ Average investment amount

$5,459

⏰ Last time a customer invested in VBTC

8 hours
VBTC investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

10%

100k - 150k

28%

50k - 100k

21%

Less than 50k

36%
πŸ‘Ά Age of investors

18 - 25

26 - 34

26%

35 - 90

73%
πŸ™‹ Legal gender of investors

Female

29%

Male

71%

Pearlers who invest in VBTC also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.85%

πŸ“Š Share price

$100.90 AUD

⛳️ DIVERSIFIED

πŸ‡¦πŸ‡Ί AUSTRALIA

🧱 MATERIALS

πŸ’Έ FINANCIALS

Find Out More

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

18.86%

πŸ“Š Share price

$57.74 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

12.86%

πŸ“Š Share price

$129.54 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

24.88%

πŸ“Š Share price

$45.04 AUD

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.71%

πŸ“Š Share price

$66.50 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

Want more shares? Try these...

VBND.AX was created on 2017-10-10 by Vanguard. The fund's investment portfolio concentrates primarily on investment grade fixed income. Vanguard Global Aggregate Bond Index (Hedged) ETF seeks to track the return of the Bloomberg Barclays Global Aggregate Float-Adjusted and Scaled Index hedged into Australian dollars before taking into account fees, expenses and tax

πŸ™Œ Performance (5Yr p.a)

-4.32%

πŸ“Š Share price

$41.90 AUD

🌏 GLOBAL

Vectus Biosystems Ltd. is a drug discovery and development company, which engages in the treatment for fibrosis and high blood pressure, which includes therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm focuses on medical research and development. The company is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. The company also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The firm has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.

πŸ™Œ Performance (5Yr p.a)

-16.95%

πŸ“Š Share price

$0.08 AUD

🧬 BIOTECHNOLOGY

Compare
Add to watchlist